Source comparison
Melanotan-1 vs Melanotan-2: Research Applications and Receptor Selectivity
Melanotan-2 (MT-2) is a seven-amino-acid cyclic analogue of alpha-MSH with broader receptor affinity than Melanotan-1. While Melanotan-1 selectively binds MC1R (the melanocyte receptor), Melanotan-2 binds MC1R, MC3R, MC4R, and MC5R with varying affinities. MC3
This comparison does not assign a generated winner or score.
- Melanotan-2 (MT-2) is a seven-amino-acid cyclic analogue of alpha-MSH with broader receptor affinity than Melanotan-1. While Melanotan-1 selectively binds MC1R (the melanocyte receptor), Melanotan-2 binds MC1R, MC3R, MC4R, and MC5R with varying affinities. MC3R and MC4R regulate appetite and energy expenditure; MC4R agonism is the mechanism behind FDA-approved obesity treatments like setmelanotide. MC5R affects sebaceous gland activity and sexual function. The source of MT-2's off-target erectile effects.
- This receptor promiscuity makes Melanotan-2 unsuitable for photoprotection research where isolating melanogenesis from metabolic or sexual pathways is required. Clinical trials use Melanotan-1 exclusively because it targets the pigmentation pathway without activating appetite suppression or sexual arousal circuits. Published comparisons show Melanotan-2 produces faster visible pigmentation (7–10 days vs 14–20 days) but with higher rates of nausea, flushing, and spontaneous erections in male subjects. Adverse events absent in Melanotan-1 protocols.
- Research-grade distinction matters here. Melanotan-1 for investigational use requires 98%+ purity and comes as lyophilised powder stored at −20°C. Once reconstituted with bacteriostatic water, it must be refrigerated at 2–8°C and used within 28 days. Temperature excursions above 8°C cause irreversible peptide bond degradation. Melanotan-2 is almost never used in formal clinical research because of its off-target effects, but it circulates widely in gray-market contexts due to faster cosmetic results.